Abstract:Platinum(IV) complexes are prodrugs of cisplatin with multiple potential advantages over platinum(II) drugs. Mitochondria play pivotal roles in producing energy and inducing death of cancer cells. Two platinum(IV) complexes, namely, c,c,t-[Pt(NH3)2Cl2(OH)(OCOCH2CH2CH2CH2PPh3)]Br and c,c,t-[Pt(NH3)2Cl2(OCOCH2CH2CH2CH2PPh3)2]Br2, were designed to explore the effect of mitochondrion-targeting group(s) on the bioactivity and cytotoxicity of platinum(IV) complexes. The complexes were characterized by electrospray ionization mass spectrometry, reverse-phase high-performance liquid chromatography, and multinuclear (1H, 13C, 31P, and 195Pt) NMR spectroscopy. The introduction of triphenylphosphonium targeting group(s) markedly influences the reactivity and cytotoxicity of the Pt(IV) complexes. The targeted complex displays more potent disruptive effect on mitochondria but less inhibitory effect on cancer cells than cisplatin. The lipophilicity of the Pt(IV) complexes is enhanced by the targeting group(s), while their reactivity to DNA is decreased. As a result, the mitochondrial morphology and adenosine triphosphate producing ability are impaired, which constitutes an alternative pathway to inhibit cancer cells. This study shows that both the reactivity of platinum(IV) center and the property of axial targeting ligand exert influences on the cytotoxicity of targeted Pt(IV) complexes. For targeting groups with pharmacological activities, their intrinsic function could enrich the anticancer mechanism of Pt(IV) complexes.

A mitochondria-targeting hetero-binuclear Ir(iii)-Pt(ii) complex induces necrosis in cisplatin-resistant tumor cells.

Mitochondrial DNA-targeting and impairment by a dinuclear Ir-Pt complex that overcomes cisplatin resistance

A Mitochondria-Targeting Dinuclear Ir-Ru Complex As a Synergistic Photoactivated Chemotherapy and Photodynamic Therapy Agent Against Cisplatin-Resistant Tumour Cells.

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

A Mitochondrion-Targeting Copper Complex Exhibits Potent Cytotoxicity Against Cisplatin-Resistant Tumor Cells Through Multiple Mechanisms of Action

An Aggregation Induced Emission Binuclear Pt(II) Complex with Mitochondria Targeting and Cell Necrosis Inducing Capability

Designing a Mitochondria-Targeted Theranostic Cyclometalated Iridium(III) Complex: Overcoming Cisplatin Resistance and Inhibiting Tumor Metastasis through Necroptosis and Immune Response

Cyclometalated Iridium(III) Complexes as Mitochondria‐targeting Photosensitizers against Cisplatin‐resistant Cells <sup>†</sup>

Cyclometalated Iridium(III) Complexes As Mitochondria-targeting Photosensitizers Against Cisplatin-resistant Cells.

Photodamaging of Mitochondrial DNA to Overcome Cisplatin Resistance by a Ru II -Pt II Bimetallic Complex.

Phosphorescent Iridium(iii)-Bis-n-heterocyclic Carbene Complexes As Mitochondria-Targeted Theranostic and Photodynamic Anticancer Agents.

Iminoamido chelated iridium(III) and ruthenium(II) anticancer complexes with mitochondria-targeting ability and potential to overcome cisplatin resistance

Enhancing Cytotoxicity of a Monofunctional Platinum Complex Via a Dual-DNA-Damage Approach.

Mitochondria-targeting monofunctional platinum(ii)-lonidamine conjugates for cancer cell de-energization

Dual-targeting tumor cells hybrids derived from Pt(IV) species and NF-κB inhibitors enables cancer therapy through mitochondrial dysfunction and ER stress and overcomes cisplatin resistance

Impact of Mitochondrion-Targeting Group on the Reactivity and Cytostatic Pathway of Platinum(IV) Complexes.

An AIE-based Monofunctional Pt(ii) Complex for Photodynamic Therapy Through Synergism of Necroptosis–ferroptosis

Mitochondria-targeted Cyclometalated Iridium (III) Complexes: Dual Induction of A549 Cells Apoptosis and Autophagy.

Oncosis-inducing Cyclometalated Iridium(iii) Complexes

Mitochondria-targeted Phosphorescent Cyclometalated Iridium(iii) Complexes: Synthesis, Characterization, and Anticancer Properties

Anticancer Cyclometalated Iridium(III) Complexes with Planar Ligands: Mitochondrial DNA Damage and Metabolism Disturbance.